Clinical Trial Update: A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-927 in combination with ABBV-368, Budigalimab (ABBV-181), and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• ABBV-368
• ABBV-927
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Cancer, Advanced Solid Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING